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Introduction 
The kidneys have various 
functions, of which the excretion from 
the body of excess water and water-
soluble waste products is one. To this 
end fluid from the blood is filtered and 
processed by the two kidneys. Each 
kidney contains a million 
microscopically sized functional units 
called nephrons, see figure 1.1. A 
nephron is composed of a filtering 
unit, the glomerulus, from where the 
filtered fluid flows into a tubule (see 
arrows), which contains different 
segments. In the regulation of 
glomerular filtration small blood 
vessels are important, which are 
positioned at the inflow and outflow 
sites of each filtering unit. They are 
called afferent and efferent arteriole, 
respectively (figure 1.1). The filtration 
function of the kidney can be harmed 
during the course of various illnesses, 
one of them being diabetes mellitus 
(45). This disease, which at present 
increases dramatically in the world is 
subdivided in two main forms (see 
below). The second designated type 2, 
is often preceded by overweight or 
obesity (13, 42). 
In the present thesis obesity 
and in particular diabetes mellitus 
have been simulated in rats, in order to investigate microvascular determinants 
that are involved in damaging the small filter-units in each kidney. We were 
particularly interested in recognizing alterations in the molecular mechanisms 
possibly related to changes in functioning and reactivity of the small feeding and 
draining arterioles of the glomeruli (figure 1.1). We studied, among others, the 












Figure 1.1. Schematic illustration of a nephron (upper 
panel), the actual functional unit of which each kidney 
contains about a million. The beginning of each 
nephron is the glomerulus, where fluid is filtered from 
the blood into the nephron. Lower panel, example of a 
light microscopic picture of a perfused glomerulus from 
a hydronephrotic kidney, with its feeding afferent 
(right side) and draining efferent arteriole (left side). 
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myogenic response, to depolarization of the cell-membrane and to the 
circulating hormone angiotensin II, with special attention to the modulating 
influence of alterations in signaling molecules generated within the so-called 
cyclo-oxygenase (COX) pathway. 
General aspects of diabetes mellitus 
In the 2nd century AD, the word diabetes, meaning “siphon”, i.e. a bent 
tube through which liquid can flow away from a vessel, was first used by the 
Greek physician Aretaeus to describe patients with great thirst and excessive 
urination. In the 17th century it was noticed that the urine of many of these 
patients had a sweet smell and taste, so the word mellitus, meaning “like 
honey,” was added to the name of the disease (2). Diabetes mellitus is seen as 
one of the main threats to human health in the 21st century (35, 62). When 
untreated it is characterized by chronic hyperglycemia, i.e. high glucose levels in 
the blood (62). Increased concentrations of glucose in the blood and body fluids 
alter, among others, the structure and function of various proteins. There are 
two main forms of diabetes mellitus.  
Type 1 diabetes, also called insulin-dependent diabetes mellitus, is due 
primarily to autoimmune-mediated destruction of beta cells in the pancreatic 
islets, resulting in absolute insulin deficiency (62). In the Netherlands 74,000 
people are affected by type 1 diabetes (1). In addition, an increase of 23% was 
found between 1980-1990 in a study that compared diabetes incidence in the 
Netherlands among children younger than 20 years of age (46). This comparison 
suggests an increase in the number of type 1 diabetic patients also in the near 
future. 
Type 2 diabetes is characterized by insulin resistance, which is defined 
by a relative insensitivity of the target tissues for insulin, resulting in a reduced 
glucose uptake (62). Of all diabetic patients 85-90% is affected by type 2 
diabetes. This means that in The Netherlands alone 526,000 people, or 3.3% of 
the total population, suffer from this disease. It is predicted that in 20 years 
time the number of type 2 diabetic individuals will increase by 35% (1). A risk 
factor for its development is obesity. One out of every 3 people with obesitas will 
develop type 2 diabetes mellitus (13, 42). 
General aspects of obesity 
The prevalence of obesity and of people with overweight in The 
Netherlands has been reported to be 1.6 million individuals, which is 10% of the 
population (3). Obesity occurs when the number of calories consumed exceeds 
the number that is metabolized, the remainder being stored in adipose (fat) 
tissue.  
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The kidney 
In addition to the excretion of excess water, waste products and foreign 
substances, the kidneys regulate extracellular fluid volume and osmolarity, 
maintain ion balance, regulate pH, and participate in endocrine pathways. The 
various segments of the functional unit, i.e. the nephron (see figure 1.1, upper 
panel), execute these functions in collaboration with the surrounding blood 
vessels. Arterial blood arriving at a nephron has passed via successively smaller 
interlobular arteries, and finally the distal interlobular artery, into the afferent 
arteriole. From there it runs into the glomerulus, where plasma without proteins 
filters out from the capillary loops into the capsule of Bowman. From there the 
filtrate flows into the first and subsequent tubular segments of the nephron 
(arrows figure 1.1). Blood leaves the glomerulus via the efferent arteriole, and 
from there it flows first through microvessels surrounding the tubular segments 
of that same nephron before finally leaving the kidney via the renal vein.  
The resistance of the pre- and postglomerular microvessels determines 
glomerular filtration rate and regulates glomerular capillary pressure. 
Determinants of filtration rate as measured in a single nephron are: single 
nephron plasma flow, glomerular capillary pressure, capillary ultrafiltration 
coefficient and systemic oncotic pressure (7). Increases in the first 3 and/or a 
decrease in the last one may increase filtration rate. Subsequent analyses 
Number of diabetic patients Number of diabetic patients with nephropathy





























Figure 1.2. Current and expected prevalence of diabetes mellitus, type 1 and type 2 combined (dashed 
line), and the concomitant (predicted) rise in diabetic nephropathy (solid line). Adapted from King et al. 
(32). 
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revealed that glomerular capillary pressure was the main determinant of 
glomerular damage (7). Glomerular capillary pressure is mainly determined by 
the resistance of the immediate preglomerular arterioles and the efferent 
arteriole (40). When a glomerulus is damaged it can not properly filter anymore. 
When this happens to many glomeruli, nephropathy or kidney failure will 
develop.  
Diabetic nephropathy 
The four main complications of diabetes mellitus are: nephropathy, 
cardiovascular disease, retinopathy and neuropathy. The latter three are beyond 
the scope of the present thesis. Diabetic nephropathy is initially characterized by 
an increased loss of albumin in the urine. This is thought to be preceded by 
hyperfiltration, which is often found in diabetic patients with normoalbuminuria. 
Clinically, more albumin in the urine is divided into micro- and 
macroalbuminuria. A slow loss of glomerular filtration capacity is thought to start 
in the microalbuminuric phase, which is characterized as an urinary albumin 
excretion between 20 and 200 µg/min. Microalbuminuria usually proceeds into 
macroalbuminuria which is defined as a urinary albumin excretion above 200 
µg/min. This phase is associated with a more prominent decline in glomerular 
filtration rate. 
Figure 1.2 shows the expected number of patients with diabetic 
nephropathy in the near future (solid line) based on the estimated increase of 
both types of diabetes mellitus combined (dashed line). It is known that 20-40% 
of the patients with type 1 diabetes mellitus will develop diabetic nephropathy, 
despite an improved glycemic control (32). As mentioned above, diabetic 
nephropathy is often preceded by a phase of hyperfiltration (e.g. 14, 17, 18, 20, 
57). In addition to possible alterations within the glomerulus itself, e.g. of the 
capillary wall, the pre- and postglomerular arterioles also may play a role in the 
development of hyperfiltration (4, 59). A decrease in preglomerular resistance is 
seen as an important determinant, while postglomerular resistance often is 
maintained (9, 61). This combination results in a heightened glomerular pressure 
causing hyperfiltration, and with longer duration, damage to the glomerular 
capillaries. A decreased preglomerular resistance can be caused by a decreased 
sensitivity for vasoactive stimuli inducing constriction, and/or an increased 
sensitivity to vasodilatory substances. 
Nephropathy in obese patients 
Not only diabetes, but also obesity can change normal renal physiology. 
Even without hyperglycemia it is already associated, among others, with an 
increase in glomerular filtration rate, increased renal plasma flow and an 
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increased urinary albumin excretion (12). The latter is considered a first sign of 
endothelial and/or podocyte dysfunction in the glomerulus (5), while 







































Figure 1.3. Schematic overview of molecular mechanisms in vascular smooth muscle cells leading to 
vasoconstriction, and of angiotensin II, pressure and membrane depolarization induced signaling. 
Membrane depolarization can be evoked, among others, by inhibition of potassium-efflux, as happens with 
various vasoconstrictors (see text). SR sarcoplasmic reticulum; MLC myosin light chain; MLCK MLC kinase; 
CaM calmodulin; PLC phospholipase C; PIP2 phosphatidylinositol 4,5-biphosphate; IP3 inositol 1,4,5-
triphosphate; IP3R IP3 receptor; Ca
2+ calcium; DAG 1,2-diacylglycerol and PKC protein kinase C. 
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mechanisms involved, however, probably differ between obesity and diabetes 
mellitus (12). 
Renal microvascular constriction or vasodilatation, and alterations in diabetic 
nephropathy 
Changes in resistance of the kidney and its glomeruli can be regulated by 
vasoconstriction or vasodilatation. This is brought about by the vascular smooth 
muscle cells in the wall of the renal arterioles, which interact with surrounding 
cells such as the endothelium, mesangial cells in the glomerulus and tubular 
epithelium. Depolarization of the vascular smooth muscle cell membrane, or the 
response of these cells to a change in transmural pressure (myogenic response), 
or their responsiveness to the circulating signaling molecule angiotensin II or to 
locally produced products of the COX pathway are all important determinants of 
their functioning. First, basic aspects of vascular smooth muscle cell contraction 
will be shortly described. Thereafter, the role of each stimulus mentioned above 
in maintaining glomerular pressure will be succinctly introduced, followed for 
each stimulus by a paragraph discussing its involvement in diabetic nephropathy. 
Vascular smooth muscle cell contraction 
Vasoconstriction is brought about by contraction of vascular smooth 
muscle cells (VSMCs). For the latter a rise in the intracellular free calcium-ion 
concentration is important, as is shown in figure 1.3 (start at Ca2+ in the black 
box). Calcium then binds to calmodulin, and the calcium-calmodulin complex 
binds in turn to MLC-kinase (MLCK) thereby stimulating phosphorylation of myosin 
(myosin-P). Myosin-P is able to interact with actin filaments resulting in VSMC-
contraction and vasoconstriction. Alternatively, when rho-kinase is activated (see 
also figure 1.3, lower right), it sustains vasoconstriction by inhibiting the 
dephosphorylation of myosin-P. It does so by converting the active myosin light 
chain (MLC) phosphatase to its inactive form (53). 
Membrane depolarization 
Membrane depolarization of VSMCs is a physiological component of many 
vasoconstrictor pathways, as is also schematically shown in figure 1.3. It can be 
evoked, among others, by inhibition of potassium-efflux by closure of potassium 
channels. Signaling pathways which lead to such closure operate either via 
activation of protein kinase C (PKC) or rho-kinase, or via inhibition of cAMP or 
cGMP. Both pathways are used by vasoconstrictors (30, 41). Membrane 
depolarization is able to cause a rise in intracellular calcium due to opening of 
voltage-gated calcium channels in the outer VSMC membrane (34, 48, 47).  
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Figure 1.4. Schematic overview of cyclo-oxygenase (COX) pathways in vascular smooth muscle cells, and how 
angiotensin II (AngII), mark numbered 1, or hyperglycemia, mark numbered 2, can influence this balance. 
Hyperglycemia has other effects as well which are not shown (e.g. glycosilation of proteins and generation of 
reactive oxygen species (51)). Two isoforms of COX, designated 1 or 2 (COX 1/2), are present in the kidney. 
PLC phospholipase C; PIP2 phosphatidylinositol 4,5-biphosphate; IP3 inositol 1,4,5-triphosphate; IP3R IP3 
receptor; Ca2+ calcium; DAG 1,2-diacylglycerol and PKC protein kinase C; PLA2 phospholipase A2; AA 
arachidonic acid; PG prostaglandin (for I2, D2 and E2).
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Interestingly, this may lead to rho-kinase activation via an as yet unknown 
mechanism (see figure 1.3) (34, 47, 48). 
In arterioles of diabetic rats the responses of potassium channels were 
found to be increased, as well as their functional availability, thereby promoting 
dilatation of these microvessels (27). The same investigators also found a 
decreased responsiveness in these rats to membrane depolarization, as evoked by 
increasing the extracellular potassium chloride concentration. This indicates that 
afferent arteriolar contractile and calcium responses are diminished in diabetes 
mellitus (10, 11). 
Myogenic response 
The myogenic response is the acute constriction of a blood vessel in 
reaction to an increase in transmural pressure, and vasodilatation when pressure 
decreases. In the kidney, it is an important mechanism to protect the glomerulus 
from changes in systemic blood pressure (36). As transmural pressure was 
increased, vascular smooth muscle cells of renal arteries exhibited a linear 
depolarization from an average resting potential of -57±2 mV at 20 mm Hg to  
-38±2.4 mV at 120 mm Hg (22). This indicates that VSMC membrane 
depolarization is involved in the myogenic response, as is also depicted in figure 
1.3. In renal arterioles the subsequent rise in intracellular calcium could be 
inhibited by L-type calcium channel blockers, suggesting that voltage-gated 
calcium entry mechanisms are responsible for the rise in intracellular calcium 
with an elevated transmural pressure (22, 25). How the vascular wall translates 
changes in transmural pressure into changes in VSMC membrane potential is at 
present unknown (15).  
In afferent arterioles of diabetic rats an impaired myogenic responsiveness was 
found, which could be restored by a high dose of the aselective COX-inhibitor 
ibuprofen (26). Therefore, an alteration in the synthesis of one or more products 
within the different COX-pathways (see below) might play a role in the reduced 
reactivity to pressure as found in diabetic rats (26). 
Angiotensin II 
Angiotensin II is a circulating hormone that also can be formed in the 
kidney. It is an important regulator of the diameters of pre- and postglomerular 
arterioles, and hence, of glomerular hemodynamics (40). It can elevate 
intracellular calcium-levels in VSMCs by stimulating calcium mobilization from 
intracellular stores, and secondly by activating calcium entry mechanisms. When 
angiotensin II binds to its AT1-receptor phospholipase C (PLC) is activated, as is 
shown in figure 1.3. Activated PLC hydrolyses phosphatidylinositol 4,5-
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biphosphate (PIP2) to inositol 1,4,5-triphosphate (IP3) and 1,2-diacylglycerol 
(DAG). IP3 binds to receptors on the sarcoplasmic reticulum where calcium 
channels are opened and stored calcium is released into the cytoplasm. DAG in 
turn, activates PKC which, among others, is thought to increase the sensitivity of 
the contractile apparatus for calcium (56). 
In diabetic pre- and postglomerular microvessels various changes in the 
effects of angiotensin II have been found: an increase in reactivity (10), no effect 
of the diabetes (10, 49) or a decreased reactivity (28, 29). The study that 
observed in afferent arterioles an increased responsiveness to angiotensin II due 
to diabetes mellitus did not investigate any underlying mechanisms (10); by 
contrast, in efferent arterioles no change was seen. One of the studies that 
reported a normal afferent arteriolar reaction to angiotensin II found that this 
could occur thanks to a modulation of superoxide dismutase that suppressed an 
altered influence of endogenous nitric oxide (NO) caused by the diabetes mellitus 
(49). A decreased reactivity to angiotensin II due to diabetes could be restored 
by feeding the rats a diet enriched with 1% myo-inositol (29). Adding myo-inositol 
to the diet resulted in a increased incorporation of myo-inositol into the 
membrane which restored the vasoconstrictor capacity to angiotensin II (29), 
myo-inositol is a precursor of IP3 (see figure 1.3). In another study the decreased 
reaction to angiotensin II could be partially restored by the aselective COX-
inhibitor indomethacin (28), again indicating an alteration in the synthesis of one 
or more products within the COX pathway (see below) due to diabetes mellitus.  
COX-pathway 
Table 1.1. Overview of prostanoids active in the kidney and their receptors with the main vasoactive effect. 
Prostanoid Constrictive Dilatory 
Thromboxane A2 TP  
PGE2 EP1, EP3 EP2, EP4 
PGI2  IP 
PGF2α FP  
PGD  DP 
Partially adapted from (8). PG prostaglandin (for E2, I2, F2α and D) 
Products of the COX-pathway, called prostanoids, are important 
mediators of renal hemodynamics (8, 23, 24, 43). As is shown schematically in 
figure 1.4, they are formed when phospholipase A2 (PLA2) is activated by a rise in 
intracellular calcium and/or by PKC. PLA2 then liberates arachidonic acid from 
membrane phospholipids. Arachidonic acid is then bound by a complex of one of 
the COX enzymes and peroxidase. It is known that there are two COX isoforms (1 
and 2) present in the kidney (60), of which COX-1 is the most abundant. The 
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complex of COX-1 or –2 with peroxidase converts arachidonic acid into PGG2 and 
PGH2, which in turn are rapidly transformed into more stable prostanoids by cell-
specific synthases (60). Prostanoids can alter vessel tone depending on which 
type is produced, as is shown in figure 1.4. For example, production of 
thromboxane A2 leads in the kidney to vasoconstriction (50) and of prostaglandin 
I2 (PGI2) to vasodilatation (19).  
Table 1.1 gives a schematic overview of the different prostanoid 
receptors present in the kidney and their main vasoactive action. Only 
prostaglandin E2 (PGE2) has both vasoconstrictive and vasodilatory properties.  
Angiotensin II can stimulate the synthesis and release of various 
prostanoids (39, 50). As is shown in figure 1.4 (see mark numbered as 1), binding 
of angiotensin II to its receptor activates PLC, which leads to a subsequent 
increase in cytosolic calcium levels via IP3. This, and the activation of PKC can 
both activate PLA2 (50). Via the latter pathway also hyperglycemia can stimulate 
PLA2 activity (16), as is indicated in figure 1.4 by number 2. Hyperglycemia has 
also other effects which are not shown in the figure such as alterations in 
metabolism, glycosylation of proteins and generation of free oxygen radicals 
(51).  
As mentioned already, in diabetic renal microvessels the aselective COX-
inhibitor indomethacin was capable of partially restoring an attenuated reaction 
to angiotensin II (28). However, which of the two COX-isoforms is involved, and 
to which extent is presently unknown. In renal microvessels a possible 
relationship between diabetes and COX-2 has not been investigated so far. 
 Diabetes and obesity models used 
Type 1 diabetes mellitus was induced in male Sprague-Dawley rats by 
injection of streptozotocin (STZ). This naturally occurring antibiotic, which is 
produced by the fungus Streptomyces achromogenes, is in sufficient dose toxic 
for the beta cells in the pancreatic islets. The glucose moiety of STZ is the 
essential component that specifically directs STZ to the beta cell. Once inside 
the beta cell it causes destruction of DNA and apoptosis. Subsequently, there are 
not enough beta cells left to produce insulin, which will result in hyperglycemia. 
The STZ-injection is often combined with subsequent partial insulin substitution, 
as was also done in most of our experiments, to prevent a too high level of 
hyperglycemia.  
As a prediabetic obesity model the genetically obese Zucker rat was used 
(33). These rats develop obesity because of leptin resistance due to a missense 
mutation in its hypothalamic receptor (55, 58). Lean control rats are genetically 
identical except for this mutation. The obese rat displays many of the health 
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problems seen in human obesity such as hyperlipidemia, late-onset hypertension, 
hypercholesterolemia, and hyperinsulinemia (6, 31, 38, 44, 52). Moreover, with 
increasing age the obese Zucker rat develops proteinuria and focal segmental 
glomerulosclerosis, ultimately leading to kidney failure (31, 38). 
Visualization of microvessels in the hydronephrotic kidney 
The isolated perfused hydronephrotic kidney was used to directly 
visualize that part of the renal microvasculature that is predominantly important 
for the regulation of glomerular capillary pressure, i.e. the distal interlobular 
arteries, afferent and efferent arterioles. Chronic hydronephrosis was induced by 
ligating the left ureter 6-8 weeks before the experiment. This results in a 
complete atrophy of the tubular elements with minimal effects on the pre- and 
postglomerular microvasculature (54). Since there are no tubular structures 
present, the tubulo-glomerular feedback mechanism is absent in this model. This 
allows for direct assessment of vascular reactivity of the microvessels just 
mentioned, without the need to account for possible indirect effects mediated 
via the tubulo-glomerular feedback mechanism. On the day of an experiment 
hydronephrotic kidneys were isolated as is extensively described in the materials 
and methods sections of chapters 2-6. Figure 1.5 shows schematically the set-up 
used for in vitro perfusion of hydronephrotic rat kidneys, as well as a picture of a 
hydronephrotic kidney in the actual set up. Perfusion flow through the kidney 
was measured with a flow-probe in the catheter between the pressurized 
reservoir and the renal artery. 
In this thesis we mainly studied the responsiveness to angiotensin II, 
added directly to the perfusion fluid, which is described in chapters 3, 4, 5 and 
6. Simultaneous measurements of distal interlobular arteries, afferent and 
efferent arterioles could often be performed. Membrane depolarization was 
evoked not only by increasing the extracellular potassium concentration 
(chapters 4 and 6), but also with barium chloride (chapter 6). The latter 
selectively blocks the inward rectifier potassium channel and could be 
conveniently used to obtain concentration-response curves (41). 
A unique property of the hydronephrotic kidney is the possibility to study 
myogenic reactivity, as was done in chapters 2 and 6. Since the individual vessels 
in this model can be visualized without exposure to surgical trauma, ischemia, 
hypoperfusion or hypoxia, the myogenic response is always present (54). 
However, since only preglomerular vessels are myogenically active (25), 
pressure-induced diameter changes were determined for distal interlobular 
arteries and afferent arterioles only. Two important characteristics of the 
myogenic response in the hydronephrotic kidney model are: a) it is quite rapid 
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with the steady state reached within seconds, and b) the degree of 
vasoconstriction is proportional to the elevation in perfusion pressure for the 





Figure 1.5. Set-up used for in vitro perfusion of hydronephrotic rat kidneys and microscopic observation of the 
periglomerular microvessels (upper panel, adapted from (37)). Lower panel shows an example of a 
hydronephrotic kidney placed in this set up. 
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Outline of this thesis 
Part I: diabetes mellitus 
Why 20-40% of the diabetic patients develop nephropathy, and the others 
do not is currently unknown. We addressed the hypothesis that a loss of 
responsiveness of pre- and/or postglomerular arterioles to certain stimuli might 
be involved. To this end, we combined the aforementioned STZ-model of 
diabetes mellitus type 1 with hydronephrosis and measured, among others, 
changes in diameter of these microvessels.  
In chapter 2, the responsiveness to pressure was investigated in control 
and diabetic rats coming from two different suppliers, as well as a possible 
difference in sensitivity to the vasodilator prostanoid PGE2 of control rats.  
In chapter 3, a study is presented on the effects in diabetes of a new 
class of drugs: selective COX-2 inhibitors. The responsiveness to angiotensin II 
was investigated and the involvement of thromboxane A2 here-in was 
determined. 
In chapter 4, we investigated whether aspecific inhibition of COX could 
restore a decreased responsiveness to angiotensin II in diabetic rats. In addition, 
a possible involvement of the vasodilatory prostanoid PGE2 was studied. 
Part II: Obesity 
In chapter 5, the influence of obesity on renal microvascular reactivity 
was studied. Obesity in humans is associated with proteinuria and an increased 
glomerular filtration, possibly related to an increase in glomerular capillary 
pressure. We investigated in obese Zucker rats which exhibited proteinuria, and 
in their lean controls, whether this is related to a chronic alteration in the 
diameter of pre- and/or postglomerular microvessels. We also investigated a 
possible change in their reactivity to angiotensin II. 
Part III: rho-kinase 
It is clear from the above that vascular tone of the smallest microvessels 
is important for proper regulation of renal hemodynamics (40). An important 
determinant of vascular tone is the contraction of vascular smooth muscle. This 
is determined not only by levels of intracellular free calcium, but also by the 
sensitivity of its contractile apparatus (53). A potential modulator of the latter is 
rho-kinase. In chapter 6, we addressed the question of a possible central role for 
rho-kinase in the regulation of periglomerular microvascular tone. 
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General discussion and summary 
Chapter 7 presents a general discussion about the findings described in 
the preceding chapters as well as some new supplemental data. 
The thesis ends with a summary of the results obtained and the 
conclusions drawn. 
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